Study: types and amounts of the most popular medication in Lithuania


2022 06 09


Last year, the number of patients, consuming reimbursable medication or using medical aids was 1.12 million. According to the analysis, conducted by the National Health Insurance Fund under the Ministry of Health (NHIF), this is more than 40 per cent of the entire Lithuanian population.

The study states that, last year, the consumption of reimbursable medication and the use of medical aids, has slightly increased, compared to the year before. Back then, the number of patients was 1.08 million, i.e. 38.8 per cent of the entire Lithuanian population.

According to calculations, the amount spent on reimbursable medication and medical aids by the Compulsory Health Insurance Fund (CHIF) including the share of the price, paid by the patient, constituted 406 million Eur, which is 50 million Eur more than the year before.

The study, conducted by the National Health Insurance Fund, also showed that the most common reimbursable medication, purchased by Lithuanian residents – as much as 72 per cent – was cardiovascular medication, while 17 per cent of the population used various reimbursable medical aids. Approximately 15 per cent used medication for gastrointestinal tract and metabolism, while approx. 14 per cent – for nervous system. Similar tendencies have been recorded in the last five years.

Meanwhile, in 2021, the highest amounts of money spent by CHIF on reimbursable medication and medical aids, including the share, covered by the patients, were spent on antineoplastic (157.2 million Eur), cardiological (68.7 million Eur) and circulatory (38.5 million Eur) medication.

NHIF has also ranked the health conditions, which required highest treatment costs from CHIF budget. The top five include: medication for hypertensive disorders – 43.39 million Eur, type 2 diabetes – 20.79 million Eur, bronchial and lung malignancies – 18.3 million Eur, malignant melanoma of the skin – 17.12 million Eur, multiple sclerosis – 16.05 million Eur.

According to experts, in recent five years, the share for the reimbursed medicine and medical aids, paid by the residents, has decreased more than three times – from 55 million Eur in 2017 to 17.55 million Eur last year. According to calculations, the average CHIF costs per single prescription was 40.8 Eur, while the average amount of the share, paid by the patients per single prescription was a mere 3 Euro.

NHIF is kindly reminding that currently all residents that are 75 years old or above, don't need to make any additional payments for reimbursable medicine and medical aids at all. The same coverage is applicable to persons with disabilities and pensioners aged 65 and above, whose insured income for the previous month was lower than 267 Euro. The payments to be made by these residents for the medication and medical aids are covered from the state budget, by transferring the funds to the CHIF. The average amount, covered for this resident per single prescription, made in December 2021, was 4.27 Eur.

The entire analysis, conducted by NHIF on the CHIF costs and patient contributions for reimbursable medication and medical aids is available here.

(Piktochart pict.)

The NHIF invites you:

Your questions are welcome by email [email protected] or phone: local (8 5) 232 2222, international +370 5 232 222